Mitsubishi UFJ Asset Management Co. Ltd. Has $384.23 Million Stock Holdings in Revvity, Inc. (NYSE:RVTY)

Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 2.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,382,338 shares of the company's stock after buying an additional 69,034 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned about 2.78% of Revvity worth $384,234,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in RVTY. Assetmark Inc. boosted its position in shares of Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company's stock valued at $30,000 after purchasing an additional 259 shares in the last quarter. Continuum Advisory LLC boosted its holdings in Revvity by 2,972.7% during the third quarter. Continuum Advisory LLC now owns 338 shares of the company's stock worth $43,000 after buying an additional 327 shares in the last quarter. Millstone Evans Group LLC bought a new position in shares of Revvity in the fourth quarter valued at $38,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of Revvity by 55.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock valued at $43,000 after acquiring an additional 138 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Revvity by 33.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company's stock worth $58,000 after acquiring an additional 131 shares in the last quarter. 86.65% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other Revvity news, insider Tajinder S. Vohra sold 5,492 shares of the business's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares of the company's stock, valued at $2,295,550.12. The trade was a 21.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joel S. Goldberg sold 15,170 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now owns 33,400 shares of the company's stock, valued at $4,232,782. This trade represents a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.68% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RVTY. Raymond James reaffirmed an "outperform" rating and set a $145.00 target price (up from $140.00) on shares of Revvity in a report on Monday, February 3rd. Bank of America upgraded shares of Revvity from a "neutral" rating to a "buy" rating and set a $138.00 target price for the company in a report on Friday, December 13th. Barclays boosted their price target on shares of Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Sanford C. Bernstein cut shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective on the stock. in a research report on Friday, January 10th. Finally, KeyCorp boosted their target price on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $136.25.

Revvity Stock Down 0.4 %

Shares of RVTY traded down $0.40 during midday trading on Monday, reaching $105.22. 160,579 shares of the stock were exchanged, compared to its average volume of 871,754. The firm has a 50 day simple moving average of $115.16 and a 200-day simple moving average of $117.14. Revvity, Inc. has a 12-month low of $97.32 and a 12-month high of $129.50. The company has a market cap of $12.64 billion, a price-to-earnings ratio of 47.59, a P/E/G ratio of 3.82 and a beta of 1.06. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the previous year, the firm earned $1.25 earnings per share. Research analysts forecast that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.27%. Revvity's dividend payout ratio (DPR) is currently 12.67%.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.